US · VVOS
Vivos Therapeutics, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Highlands Ranch, CO 80129
- Website
- vivos.com
Price · as of 2024-12-31
$0.81
Market cap 8.25M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $20.26 | +2,409.91% |
| Intrinsic Value(DCF) | $113.68 | +13,983.25% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $186.00 | $86.99 | $11.26 | $0.00 | $0.00 |
| 2021 | $72.75 | $138.03 | $2,337.42 | $0.00 | $0.00 |
| 2022 | $8.65 | $22.37 | $0.00 | $0.00 | $0.00 |
| 2023 | $4.83 | $405.13 | $0.00 | $0.00 | $56.47 |
| 2024 | $3.69 | $20.26 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Vivos Therapeutics, Inc.'s (VVOS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $20.26
- Current price
- $0.81
- AI upside
- +2,409.91%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$113.68
+13,983.25% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VVOS | Vivos Therapeutics, Inc. | $0.81 | 8.25M | +2,410% | +13,983% | — | — | -1.66 | 2.33 | 1.23 | -1.31 | — | 3.91 | 60.00% | -74.32% | -74.09% | -266.25% | -562.91% | -85.62% | 0.19 | — | 1.50 | 1.34 | 0.45 | -8007.00% | 891.00% | 400.00% | -71.58% | -2.55 | -668.13% | 0.00% | 0.00% | 27.53% | -1.23 | -1.04 | 0.92 | -9.26 |
| ADGM | Adagio Medical Holdings, … | $1.00 | 15.22M | +1,418% | -58% | — | +543% | -0.21 | 0.81 | 59.89 | -0.19 | — | -15.73 | -620.07% | -23226.77% | -19986.25% | 133.87% | 157.35% | -271.53% | 0.82 | 56.70 | 3.27 | 2.66 | 0.07 | -2716.00% | -1033.00% | 1971.00% | -193.09% | -3.79 | 78.34% | 0.00% | 0.00% | 256.59% | -0.19 | -0.38 | 43.83 | -5.52 |
| AEMD | Aethlon Medical, Inc. | $2.01 | 1.53M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| ALUR | Allurion Technologies Inc… | $1.17 | 9.09M | +15,409% | -17% | — | +29,866% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| COCH | Envoy Medical, Inc. | $0.72 | 15.07M | +3,147% | -23% | — | +2,867% | -1.16 | -1.39 | 116.08 | -2.03 | — | -1.39 | -229.78% | -8558.22% | -9242.22% | 217.79% | 381.46% | -226.68% | -1.04 | -23.60 | 1.24 | 0.84 | -0.72 | -4134.00% | -2880.00% | 977.00% | -72.47% | -2.38 | 374.98% | 9.37% | -10.90% | 9.37% | -2.09 | -2.13 | 179.09 | -39.33 |
| CODX | Co-Diagnostics, Inc. | $2.30 | 2.57M | +1,244% | +270% | — | +1,660% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| LPCN | Lipocine Inc. | $9.96 | 55.3M | +2,939% | -66% | -60% | — | 2199.00 | 0.87 | 1.64 | 2.93 | — | 0.87 | 100.00% | -10.31% | 0.07% | 0.04% | 92.79% | 0.04% | 0.00 | — | 14.75 | 14.38 | 5.57 | -9995.00% | -49280.00% | -8896.00% | -7.14% | -0.81 | 113.94% | 0.00% | 0.00% | 7.81% | 2.83 | 2.49 | -0.29 | -3.70 |
| NVNO | enVVeno Medical Corporati… | $10.00 | 165.03K | — | — | — | — | -0.07 | 0.04 | — | 1.91 | — | 0.04 | 0.00% | — | — | -49.39% | -3781.90% | -46.63% | 0.03 | — | 20.88 | 20.60 | 0.03 | -3351.00% | — | -1067.00% | -1122.35% | -8.04 | -2678.57% | 0.00% | 0.00% | 0.00% | 1.70 | 2.41 | — | -5.04 |
| OSRH | OSR Holdings, Inc. | $0.41 | 10.58M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
- CEO
- R. Kirk Huntsman
- Employees
- 109
- Beta
- 6.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($113.68 ÷ $0.81) − 1 = +13,983.25% (DCF, example).